BenzingaOctober 21, 2026 at 9:51 AM NY6 Days Ago
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316
Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1309 to $1316.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
